mhurhangee/ep-ind-claims huggingface dataset:
An image processing apparatus configured to process a plurality of captured images (Gi) of cell cultivation acquired using an imaging apparatus, the imaging apparatus including a container accommodating a liquid and an observation target S in the liquid, whereby a meniscus is formed on the liquid surface of the liquid, and an imaging unit configured to image the container a plurality of times while changing a position of an observation region by relatively moving at least one of the container or the imaging unit with respect to the other, whereby a respective captured image (Gi) is acquired in each observation region smaller than the container while causing a part of the adjacent observation regions to overlap, the apparatus comprising: an overlapping region selection unit configured to select, for each overlapping region (K1-K4), the captured image (Gi) overlapping the overlapping region (K1-K4), that is closest to a center of the container, as the image of the overlapping region; and a composite image generation unit configured to generate a composite image (Gs) by linking the plurality of captured images (Gi) and the selected images, wherein a respective selected image is used in each overlapping region (K1-K4). an overlapping region selection unit configured to select, for each overlapping region (K1-K4), the captured image (Gi) overlapping the overlapping region (K1-K4), that is closest to a center of the container, as the image of the overlapping region; and a composite image generation unit configured to generate a composite image (Gs) by linking the plurality of captured images (Gi) and the selected images, wherein a respective selected image is used in each overlapping region (K1-K4).
A hydrogen gas composition comprising the following gas contaminants in the following concentrations in a hydrogen gaseous matrix, expressed in μmol/mol with respect to the total number of moles of gas in the hydrogen gas composition as a whole: - sulphur compound(s): at least 0.002 μmol/mol and at most 0.20 μmol/mol, - formaldehyde (HCHO): at least 0.05 μmol/mol at most 0.50 μmol/mol, - formic acid (HCOOH): at least 0.05 μmol/mol and at most 0.50 μmol/mol, - ammonia (NH 3): at least 0.050 μmol/mol and at most 0.50 μmol/mol, - halogenated compound(s): at least 0.020 μmol/mol and at most 0.20 μmol/mol, the hydrogen gas composition comprising either ammonia (NH 3) or formaldehyde (HCHO) but not ammonia and formaldehyde simultaneously. - sulphur compound(s): at least 0.002 μmol/mol and at most 0.20 μmol/mol, - formaldehyde (HCHO): at least 0.05 μmol/mol at most 0.50 μmol/mol, - formic acid (HCOOH): at least 0.05 μmol/mol and at most 0.50 μmol/mol, - ammonia (NH 3): at least 0.050 μmol/mol and at most 0.50 μmol/mol, - halogenated compound(s): at least 0.020 μmol/mol and at most 0.20 μmol/mol,
An image display apparatus comprising: a signal control unit for receiving an input of an image signal, and converting to a signal for alternately displaying a right eye image and a left eye image, wherein said signal is converted so that each consecutive right eye image and left eye image is displayed twice over two consecutive periods respectively; a display panel, input with the signal converted by the signal control unit, for alternately displaying each of said consecutive right eye images and left eye images, wherein each of said right and left eye images is caused to be written to the display panel consecutively a first time over a first display writing period and a second time over a second display writing period; a surface light source for radiating the display panel from a rear surface; a shutter control unit for generating a timing signal indicating a switching timing of the right eye image and the left eye image with respect to viewing eyeglasses including a right eye shutter and a left eye shutter; and a surface light source control unit for causing the surface light source to emit light only in a time period shorter than an open period of the shutter (200a, 200b) according to the switching of the right eye image and the left eye image, said time period starting during the time when a respective right eye image written for the second time, or left eye image written for the second time, is displayed over the entire display panel, and ending before the shutter for the other one of said right eye image or left eye image next opens. a signal control unit for receiving an input of an image signal, and converting to a signal for alternately displaying a right eye image and a left eye image, wherein said signal is converted so that each consecutive right eye image and left eye image is displayed twice over two consecutive periods respectively; a display panel, input with the signal converted by the signal control unit, for alternately displaying each of said consecutive right eye images and left eye images, wherein each of said right and left eye images is caused to be written to the display panel consecutively a first time over a first display writing period and a second time over a second display writing period; a surface light source for radiating the display panel from a rear surface; a shutter control unit for generating a timing signal indicating a switching timing of the right eye image and the left eye image with respect to viewing eyeglasses including a right eye shutter and a left eye shutter; and a surface light source control unit for causing the surface light source to emit light only in a time period shorter than an open period of the shutter (200a, 200b) according to the switching of the right eye image and the left eye image, said time period starting during the time when a respective right eye image written for the second time, or left eye image written for the second time, is displayed over the entire display panel, and ending before the shutter for the other one of said right eye image or left eye image next opens.
Temperature control device for an NMR sample tube, wherein multiple interleaved, concentric flow channels (28, 31; 40, 41, 42; 50, 51) for temperature control fluid extending coaxially with respect to a cylindrical interior space for holding the NMR sample tube are constituted around said interior space, wherein said temperature control device is constituted such that it is closed toward the interior space in an axial end region and, in an axial end region at the opposite end thereto, open to the interior space for inserting the NMR sample tube into said interior space, wherein, in a counter flow region, adjacent flow channels (28, 31; 40, 41, 42; 51) are interconnected through a fluid passage (34, 43, 44) at one axial end in such a way that the direction of flow of a fluid flow in the flow channels (28, 31; 40, 41, 42; 51) of the counter flow region is reversed with respect to the corresponding adjacent flow channel (28, 31; 40, 41, 42; 51) in the counter flow region, wherein the outermost flow channel (28; 51) of the counter flow region has a fluid inlet at one axial end, wherein the innermost flow channel (31; 42) of the counter flow region has a fluid passage to the interior space at one axial end that faces toward the axial end region that is closed, and wherein the temperature control device moreover comprises the NMR sample tube that is arranged in the interior space, at least one of the flow channels (28, 31; 40, 41, 42; 50, 51), namely the outermost flow channel (28; 50) of the temperature control device and/or the next outermost flow channel (31; 40; 51) of the temperature control device has a fluid outlet at one axial end, through which at least part of a temperature-controlling fluid flow that is conveyed along the outermost flow channel (28; 50) of the temperature control device can escape from the temperature control device without passing completely through all of the flow channels (28, 31; 40, 41, 42; 51) of the counter flow region, and that the temperature control device is constituted such that of a total temperature-controlling fluid flow that flows to the temperature control device, at least 50% can escape through the fluid outlet at the axial end of the outermost flow channel (28; 50) or the next outermost flow channel (31; 40; 51).
An X-ray tube target having a structure in which a carbon base material is bonded with an Mo base material or Mo alloy base material with a joint layer disposed therebetween, wherein the joint layer comprises an MoNbTi diffusion phase, an NbTi alloy phase, an Nb-rich phase and a ZrNb alloy phase.
A solid form of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide, which (i) exhibits at least the following characteristic X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at approximately 11.2, 12.5, 13.2, 14.5 and 16.3, wherein the term "approximately" means that there is an uncertainty in the measurements of the degrees 2θ of ± 0.3 (expressed in degrees 2θ), or (ii) exhibits an endothermic peak in its DSC thermograph at 151 ± 3°C, wherein the solid form is Form 1.
A composition comprising an isolated HGF/IgG complex or a pharmaceutical composition comprising an isolated HGF/IgG complex and a pharmaceutically acceptable excipient, wherein the HGF/IgG complex comprises recombinant human HGF and human non-specific IgG.
A preparation method for a silk fibroin nerve graft fused with NT-3 comprising the following steps: synthesizing a gene fragment containing a silk fibroin light chain and NT-3, connecting the fragment to a pET-30 expression vector, and transferring the obtained recombinant expression vector into BL21 Escherichia coli to obtain a fusion protein; mixing the fusion protein and a silk fibroin solution to obtain a mixed protein solution, placing a silk fibroin fiber web in a mold, pouring the mixed protein solution in the mold, and performing freeze drying to form a nerve conduit; and after deformation processing, finally obtaining a silk fibroin nerve graft having NT-3 activity.
A reduced caloric diet in combination with an mTOR protein kinase inhibitor for use in the treatment of cancer: said reduced caloric diet is a fasting mimicking diet and provides at most 1000 kcal per day said reduced caloric diet is provided to a subject for a first time period of 5 to 21 days and said mTOR protein kinase inhibitor is administered to the subject before during or after said first time period.
A method of washing a cold and hot milk dispensing apparatus, which comprises a pump having an inlet and a delivery side and driven by a motor, with the inlet being hydraulically selectively connected to a milk inlet duct for milk suction or to a washing inlet duct for water suction, an outlet duct connected to the delivery side and ending with a dispensing outlet, wherein the outlet duct is connected to a steam generator via a steam duct which opens into the outlet duct for supplying steam into the outlet duct, wherein steam supply into the outlet duct is enabled during hot milk dispensing and is disabled during cold milk dispensing, characterised in that the method comprises, after a dispensing step: - if cold milk was dispensed, carrying out a first washing cycle which comprises carrying out a first washing step comprising sucking in water by means of the pump from the washing inlet duct while disabling steam supply to thereby clean the outlet duct downstream of the steam duct and the dispensing outlet with unheated water, and - if hot milk was dispensed, carrying out a second washing cycle which comprises carrying out a first washing step comprising sucking in water by means of the pump from the washing inlet duct while enabling steam supply into the outlet duct to thereby clean the outlet duct downstream of the steam duct and the dispensing outlet with heated water. - if cold milk was dispensed, carrying out a first washing cycle which comprises carrying out a first washing step comprising sucking in water by means of the pump from the washing inlet duct while disabling steam supply to thereby clean the outlet duct downstream of the steam duct and the dispensing outlet with unheated water, and - if hot milk was dispensed, carrying out a second washing cycle which comprises carrying out a first washing step comprising sucking in water by means of the pump from the washing inlet duct while enabling steam supply into the outlet duct to thereby clean the outlet duct downstream of the steam duct and the dispensing outlet with heated water.
A filter holding system for holding an optical filter to a mask casing of a welding mask, the filter holding system comprising: a holding frame body configured to support and accommodate the optical filter; a connecting mechanism provided on the holding frame body, the connecting mechanism being configured to connect and disconnect the holding frame body to and from the mask casing, wherein the connecting mechanism is moveable between a disconnect position and a connect position; when at the disconnect position, the connecting mechanism disconnects the holding frame body from the mask casing such that the holding frame body and the mask casing are separable from each other; and when at the connect position, the connecting mechanism connects the holding frame body to the mask casing, characterized in that the connecting mechanism further comprises a connecting pin, a driving block and a manipulating unit; when at a disconnect position, the connecting pin is accommodated in a connecting pin accommodating cavity of the holding frame body; when at a connect position, the connecting pin extends out of a lateral opening of the connecting pin accommodating cavity and is inserted into an accommodating cavity of the mask casing; and wherein the driving block connects the connecting pin and the manipulating unit such that the connecting pin is configured to be moved with the manipulating unit to switch between the disconnect position and the connect position. a holding frame body configured to support and accommodate the optical filter; a connecting mechanism provided on the holding frame body, the connecting mechanism being configured to connect and disconnect the holding frame body to and from the mask casing, wherein the connecting mechanism is moveable between a disconnect position and a connect position; when at the disconnect position, the connecting mechanism disconnects the holding frame body from the mask casing such that the holding frame body and the mask casing are separable from each other; and when at the connect position, the connecting mechanism connects the holding frame body to the mask casing, characterized in that the connecting mechanism further comprises a connecting pin, a driving block and a manipulating unit; when at a disconnect position, the connecting pin is accommodated in a connecting pin accommodating cavity of the holding frame body; when at a connect position, the connecting pin extends out of a lateral opening of the connecting pin accommodating cavity and is inserted into an accommodating cavity of the mask casing; and wherein the driving block connects the connecting pin and the manipulating unit such that the connecting pin is configured to be moved with the manipulating unit to switch between the disconnect position and the connect position.
An anti-MIF antibody in combination with a glucocorticoid for use in the treatment of inflammation, wherein the antibody is an anti-oxMIF antibody, and wherein the anti-MIF antibody is selected from the following group: anti-MIF antibody RAB9, i.e. an antibody with a light chain as deposited as DSM 25111 and a heavy chain as deposited as DSM 25113, RAB4, i.e. an antibody with a light chain as deposited as DSM 25110 and a heavy chain as deposited as DSM 25112 and/or RAB0, i.e. an antibody with a light chain as deposited as DSM 25114 and a heavy chain as deposited as DSM 25115, or RAM9, i.e. an antibody with a light chain as deposited as DSM 25859 and a heavy chain as deposited as DSM 25860, RAM4, i.e. an antibody with a light chain as deposited as DSM 25861 and a heavy chain as deposited as DSM 25862 or RAM0, i.e. an antibody with a light chain as deposited as DSM 25863 and a heavy chain as deposited as DSM 25864.
Device for the positionally correct fixing of a movable element arranged on at least one upper partial receiving unit, for the production of elastomer products, having a drive unit, a guide unit, an engagement element, the movable element with the upper partial receiving unit, and - a lower partial receiving unit arranged in a stationary manner on the guide unit, - an engagement element which is mounted displaceably on the guide unit and the lower partial receiving unit and can be displaced by means of the drive unit, - wherein the upper and the lower partial receiving unit (5, 6) can be positioned with respect to one another in such a way that they form a receptacle for the engagement element into which the engagement element can be moved and can be brought in such a way into a stopped position in which the engagement element assumes the greatest possible distance from the drive unit, and - wherein the engagement element has a conical contour in its longitudinal extent. - a lower partial receiving unit arranged in a stationary manner on the guide unit, - an engagement element which is mounted displaceably on the guide unit and the lower partial receiving unit and can be displaced by means of the drive unit, - wherein the upper and the lower partial receiving unit (5, 6) can be positioned with respect to one another in such a way that they form a receptacle for the engagement element into which the engagement element can be moved and can be brought in such a way into a stopped position in which the engagement element assumes the greatest possible distance from the drive unit, and - wherein the engagement element has a conical contour in its longitudinal extent.
A container comprising a pharmaceutical composition, being a solution and being suitable for administration with a nebulizer comprising (i) 0.0005% to 0.008% w/w of tiotropium or a pharmaceutically acceptable salt thereof; (ii) water; (iii) a complexing agent, the complexing agent being disodium EDTA and present at a concentration of 0.01% by weight; and (iv) 0.9% by weight sodium chloride wherein the pH of the composition ranges from 2.2 to 2.9, and said composition is free of quaternary ammonium preservatives. (i) 0.0005% to 0.008% w/w of tiotropium or a pharmaceutically acceptable salt thereof; (ii) water; (iii) a complexing agent, the complexing agent being disodium EDTA and present at a concentration of 0.01% by weight; and (iv) 0.9% by weight sodium chloride
A laminating roller (10, 28, 100) for laminating a sheet of a packaging laminate (23, 25, 31), said roller comprising at least one groove extending along the periphery of said roller and forming a border between two circumferential portions of said roller, wherein each of said two circumferential portions are extending continuously along the groove, and wherein the groove enables an elastic surface of the laminating roller to displace laterally.
A method of evaluating a patient's risk of developing Progressive Multifocal Leukoencephalopathy, the method comprising: i) determining, in a serum or plasma sample of the patient, an anti-JC Virus antibody titer, wherein the anti-JCV antibody titer is determined by an ELISA assay comprising the following steps: (a) forming a reaction mixture comprising an aliquot of sample and a substrate on which is disposed Highly Purified Viral-Like Particles (HPVLPs), and (b) detecting the level of anti-JCV antibody bound to said substrate on which is disposed HPVLPs; wherein the anti-JCV antibody titer is expressed as an index value, wherein the index value is determined by normalizing an optical density value of the sample to a cut-off calibrator adjusted to have an nOD of 1, and a positive control is adjusted to have an nOD of 1.3; wherein the cut-off calibrator and positive control comprise a mixture of serum positive for anti-JCV antibodies and serum negative for anti-JCV antibodies, and wherein a negative control comprises anti-JCV antibody negative serum and has an nOD of 0.1; and ii) determining the patient to be at high risk of developing PML if the anti-JCV antibody index value is determined to be > 1.5. i) determining, in a serum or plasma sample of the patient, an anti-JC Virus antibody titer, wherein the anti-JCV antibody titer is determined by an ELISA assay comprising the following steps: (a) forming a reaction mixture comprising an aliquot of sample and a substrate on which is disposed Highly Purified Viral-Like Particles (HPVLPs), and (b) detecting the level of anti-JCV antibody bound to said substrate on which is disposed HPVLPs; wherein the anti-JCV antibody titer is expressed as an index value, wherein the index value is determined by normalizing an optical density value of the sample to a cut-off calibrator adjusted to have an nOD of 1, and a positive control is adjusted to have an nOD of 1.3; wherein the cut-off calibrator and positive control comprise a mixture of serum positive for anti-JCV antibodies and serum negative for anti-JCV antibodies, and wherein a negative control comprises anti-JCV antibody negative serum and has an nOD of 0.1; and (a) forming a reaction mixture comprising an aliquot of sample and a substrate on which is disposed Highly Purified Viral-Like Particles (HPVLPs), and (b) detecting the level of anti-JCV antibody bound to said substrate on which is disposed HPVLPs; ii) determining the patient to be at high risk of developing PML if the anti-JCV antibody index value is determined to be > 1.5.
The Salmonella enterica strain deposited with the German Type Culture Collection (Deutsche Sammlung von Mikrorganismen und Zellkulturen (DSMZ)) on November 27, 2012 under accession number DSM 26682.
An oral care implement comprising a head, a reservoir for containing a plurality of active agents at least one outlet, a delivery device designed in the form of a pump for delivering a predetermined amount of the active agent and comprising a gas-generating cell or microcell, and a delivery device actuator comprising an internal switch adapted to activate the pump; characterised in that the internal switch of the delivery device actuator is adapted to activate the pump upon the mechanical action of brushing with the oral care implement; and in that the delivery device actuator comprises an adjustable switch to select one of a plurality of active agent treatments.
A tubular actuator for driving a windable element in a building, comprising: - in a tube having a longitudinal axis (X-X'), a reduction gear and an output shaft at a first end of the tube and - a fixed-point in two portions at a second end of the tube, the fixed-point comprising a first portion (20; 20') at least partially outside the tube and a second portion (40; 40') assembled in the tube, wherein the first portion comprises at least one torque and weight-bearing axial extension (24, 24', 25, 25'), this torque and weight-bearing axial extension being capable of being inserted into at least one recess (44, 44', 45, 45') of the second portion and being locked in translation along the longitudinal axis relative to the tube of the actuator by a first locking means (27, 28, 34, 35, 37, 38; 28', 34, 35,37, 38). - in a tube having a longitudinal axis (X-X'), a reduction gear and an output shaft at a first end of the tube and - a fixed-point in two portions at a second end of the tube,